Texas Retina Associates is honored to have randomized the first patient in EyePoint Pharmaceuticals’ Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial of EYP-1901 for patients with wet macular degeneration. 

EYP-1901 is vorolanib, a sustained release tyrosine kinase inhibitor with activity against all vascular endothelial growth factor (VEGF) receptors. It has shown potential to reduce treatment burden in patients with wet macular degeneration. Similar to current FDA-approved anti-VEGF treatments, EYP-1901 is delivered with a single intravitreal injection in our office. 

Thank you to our outstanding research team for achieving this milestone with special appreciation to our lead Clinical Research Coordinator for this trial, Jessica Flores. Texas Retina Associates’ Director of Clinical Research for Dallas Ashkan Abbey, MD, serves as Principal Investigator. We look forward to continuing to enroll patients in this important clinical trial. 

Click here to learn more about this achievement and clinical trial.

You can learn more about all of the clinical trials currently available at Texas Retina Associates here.